NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) (“NeuroScientific” or “the company”) has been informed by the Human Research Ethics Committee (HREC) it rejected the Company’s planned Phase I Clinical Trial for EmtinB™.
In making its decision, HREC determined that at this stage the supporting documentation did not sufficiently address the risk-benefit profile to justify the conduct of the planned Phase I Clinical Trial.The HREC decision to not approve the Phase I Clinical Trial was unexpected and the Company is seeking clarification on the rationale for the decision to determine what steps can be taken to proceed with the Phase I Clinical Trial.
The market will be updated when more information is available.
